Rimonabant
-
Subject Areas on Research
- A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation.
- Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation.
- Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands.
- Cannabinoid CB(1) receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues.
- Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks.
- Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential.
- Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity.
- Effect of rimonabant on weight and cardiometabolic risk factors.
- Endocannabinoid receptor antagonists and other emerging pharma-cological strategies for weight reduction.
- Endocannabinoid system overactivity and the metabolic syndrome: prospects for treatment.
- Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity.
- Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism.
- Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation.
- Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity.